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Abstract
Background: Antimicrobial stewardship programs have been widely introduced in hospitals as a response to
increasing antimicrobial resistance. Although such programs are commonly used, the long-term effects on
antimicrobial resistance as well as societal economics are uncertain.
Methods: We performed a cost analysis of an antimicrobial stewardship program introduced in Malmö, Sweden
in 20 weeks 2013 compared with a corresponding control period in 2012. All direct costs and opportunity costs
related to the stewardship intervention were calculated for both periods. Costs during the stewardship period
were directly compared to costs in the control period and extrapolated to a yearly cost. Two main analyses were
performed, one including only comparable direct costs (analysis one) and one including comparable direct and
opportunity costs (analysis two). An extra analysis including all comparable direct costs including costs related to
length of hospital stay (analysis three) was performed, but deemed as unrepresentative.
Results: According to analysis one, the cost per year was SEK 161 990 and in analysis two the cost per year was
SEK 5 113. Since the two cohorts were skewed in terms of size and of infection severity as a consequence of the
program, and since short-term patient outcomes have been demonstrated to be unchanged by the intervention,
the costs pertaining to patient outcomes were not included in the analysis, and we suggest that analysis two
provides the most correct cost calculation. In this analysis, the main cost drivers were the physician time and
nursing time. A sensitivity analysis of analysis two suggested relatively modest variation under changing
assumptions.
Conclusion: The total yearly cost of introducing an infectious disease specialist-guided, audit-based antimicrobial
stewardship in a department of internal medicine, including direct costs and opportunity costs, was calculated to
be as low as SEK 5 113.
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Background
The emergence of antimicrobial resistance is de-
scribed by the World Health Organization to be “an
increasingly serious threat to global public health that
requires action across all government sectors and so-
ciety” [1]. Several factors contribute to the spread of
antimicrobial resistance in the community. The mis-
use or overuse of antibiotics in human medicine is
one such factor, and possibly the factor that has been
discussed and addressed the most [2].
The term ‘Antimicrobial stewardship programs’ (ASPs)
is an umbrella definition that in practice may encompass
several different measures. ASPs have been introduced
widely to address the misuse of antibiotics in human
medicine [3, 4], and hospital programs may include re-
strictive measures as well as persuasive interventions in-
cluding audit and feedback methodology [5]. There is no
consensus on what outcomes should be monitored when
an ASP is launched, and opinions on what outcomes are
most important vary from different perspectives [6]. Un-
fortunately, there is still no conclusive evidence that a
reduction of antibiotic use results in reduced antimicro-
bial resistance [7]. Due to these uncertainties, it is im-
portant to monitor individual patient outcomes during
the launch of antimicrobial stewardship programs to
make sure that programs do not introduce harm. We
also believe that it is necessary to analyse the economic
consequences of ASPs, to make sure that decisions to
introduce ASPs can be objectively compared with other
potential efforts.
The full health-economic consequences of antimicro-
bial stewardship programs are complex to calculate due
to uncertainties in long-term effects on costs and bene-
fits, as well as due to uncertainties in attributable costs
and effects of the infection. Recently, systematic ap-
proaches to address such health economic evaluations
have been suggested [8]. Besides the implementation
costs and operational costs of the program itself, it is
necessary to include the direct costs of antibiotics, in-
cluding time for handling and materials as well as
costs related to patients outcomes, normally hospital
lengths-of-stay. It would be desirable to include a cal-
culation of the societal effects, but such calculations
are at best uncertain.
In this investigation, the aim was to study the economic
consequences of introducing an individual audit-based
ASP in Sweden, a region with a limited prior history of
systematic ASPs. The program has been demonstrated to
be successful in substantially reducing antibiotic use and
maintaining favourable patient outcomes [9]. However,
since individual audit and feedback-based programs are
generally considered as cost-intensive, and since alterna-
tive ways of performing stewardship interventions exist, a
follow-up cost analysis was deemed valuable. The rates of
Clostridium difficile-associated disease (80 cases per
100,000 individuals) [10] as well as the rates of carriage of
resistant bacteria [11] are comparatively low in Sweden,
with rates of E. coli with extended-spectrum betalacta-
mase production at 5 % and rates of methicillin-resistant
isolates among Staphyloccus aureus at around 1 %. Since
this particular program was introduced during ‘normal’
circumstances, i.e. not in response to an outbreak of re-
sistant bacteria or Clostridium difficile, we believe that the
results can be generalizable to other regions with low pro-
portions of antimicrobial resistance.
Methods
Study setting
The original study [9] was performed in the Department
of Internal Medicine, Malmö at Skåne University Hospital
in Sweden, a hospital with approximately 1100 beds at
two sites. The department is a secondary care unit serving
patients in general internal medicine, including mainly
elderly patients with one or more chronic underlying con-
dition. The geographical area that the hospital serves has a
population of approximately 700 000.
The antibiotic stewardship intervention study design
This cost analysis is based on a quasi-experimental trial
with an historic control of the introduction of an anti-
biotic stewardship intervention. The intervention was
performed in four wards of internal medicine, from
April 1 through June 20, 2013 as well as August 26
through October 21, 2013. Considering the variability of
influenza seasons, the intervention was not performed
during influenza seasons. All patients that received, or
were prescribed, antibiotics were audited by an infec-
tious disease-specialist twice weekly. The control group
consisted of individuals treated with antibiotics during
admission to the same wards in the corresponding time
period 2012, when no active intervention was in place.
An ATC-code based search of the computerized medical
records unambiguously identified all cases that had re-
ceived antibiotics in the two periods, audited or not.
Patients receiving antibiotic prophylaxis only were ex-
cluded from the analysis [9]. All audits were performed
as real-time discussions, including feedback, between
the auditing ID specialist and the ward physician. Dis-
cussions concerning approximately 25–30 patients took
place on each audit day. In some instances, a brief
renewed physical examination was performed. All pa-
tients with antibiotics were discussed on each occasion,
even though the same patient had been discussed in
prior visits. Since the ward doctors generally were re-
sponsible for a third of patients in a ward, the time spent
for each doctor in the ward was approximately 15–
20 min per occasion (the four wards had separate med-
ical staff ), including write-ups. Even though the patients
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in the original study were not randomized, they were
well-balanced with regards to age, gender and under-
lying diseases [9].
Definition of resource categories and unit costs
The present cost analysis is based on the results from
the antimicrobial stewardship program that was intro-
duced in the department of internal medicine in south-
ern Sweden in 2013. The clinical aspects of the study
have been evaluated and published. This cost analysis is
based on the same data [9].
Resource utilization was estimated for audits four
hours per time twice weekly for both the specialist phys-
ician from the department of infectious diseases and a
physician from the study wards. Resource utilization for
nurses was estimated based on an assumption about
18 min for preparation and distribution of each dose of
IV antibiotics to the patients (the time was based on an
inquiry performed at hospital wards) and 6 total minutes
per day for administration of each oral antibiotic (nor-
mally two to three doses per day).
The implementation costs of the program were based
on the time needed to plan the project and provide writ-
ten and oral information of the project to colleagues to
the involved staff. Costs for physicians were calculated
based on information from the Swedish Medical associ-
ation 2015 [12], while the costs for nurses were calcu-
lated based on information from Statistics Sweden
regarding average salaries in 2014 for professionals in
health care [13]. Wages were adjusted to 2015 price level
with a labour cost index from Statistics Sweden for em-
ployees in the sector of human health and social work
activities [14]. A payroll tax for county councils of 41 %
was added [15]. Even though the actual audits at the
wards could sometimes be performed in less than four
hours, though not measured to the minute, costs were
based on four-hour audits on each of the forty audits to
apply the most conservative cost estimate.
Antibiotic costs were calculated from official price lists
in all cases except for ampicillin where information was
collected through personal communication with an ad-
ministration staff in the Southern health care region. For
IV antibiotics a daily cost was estimated based on aver-
age doses in the medical charts and unit prices from a
local database. This database includes information about
drugs where the price has been negotiated between
pharmaceutical companies and the Southern health care
region [16]. Similarly, the cost of oral antibiotics was es-
timated from the average doses in the medical charts
and unit prices from FASS [17]. Whereas all IV antibi-
otics were given in the wards, the proportion of oral
antibiotics given in the wards was calculated in order to
apply nurse preparation costs only for in-hospital
treatment.
Material costs for administration of IV treatment were
estimated for syringes, needles, peripheral venous cath-
eter, liquids (sodium chloride or sterile water), etc. at
SEK15.70. An assumption was made that peripheral ven-
ous catheters were changed every fourth day [18].
Indirect cost for production losses are not included
since the median age of patients was 83 years [9]. All
costs are expressed in SEK in 2015 price level. Unit costs
used in the calculations are presented in Table 1. The
average exchange rate in 2015 was 1 USD = SEK 8.435
and 1 EUR = SEK 9.356 [19].
Table 1 Unit costs of each resource category (in SEK, 2015
price level)
Type of resource Unit cost Source
Implementation cost (one-time cost) 13 620.00 Estimated
Hospital stay department of internal
medicine (per day)
4 643.00 [26]
Audit with specialist in infectious
diseases (per four hours)
2 348.00 [12, 15]
Resident physician in internal
medicine (per four hours)
1 536.00 [12, 15]
Materials used per dose
of IV treatment
15.70 Assumption
Nurse time (18 min per
dose of IV treatment)
95.22 Assumption
and [13–15]







- cefotaxim 23.18 [16]
- bensylpenicillin 36.00 [16]
- cloxacillin 39.90 [16]
- ampicillin 252.00 Personal
communication
- piperacillin-tazobactam 43.50 [16]
- imipenem 83.25 [16]
- meropenem 71.70 [16]
Oral antibiotics (average cost per day)
- phenoxymethylpenicillin 7.11 [17]
- amoxicillin 3.15 [17]
- amoxicillin-calvulanate 15.30 [17]
- dicloxacillin 19.62 [17]
- ciprofloxacin 5.20 [17]
- trimethoprim-sulfamethoxazole 5.65 [17]
- tetracycline 8.35 [17]
- clindamycin 14.73 [17]
- metronidazole 7.10 [17]
- nitrofurantoin 3.51 [17]
- pivmecillinam 23.05 [17]
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Data analysis
The antimicrobial stewardship program was imple-
mented during five months. The costs for the program
was calculated for these five months and then extrapo-
lated to one whole year, with the exception of the imple-
mentation cost. This extrapolation may not reflect a true
yearly cost as monthly costs, as well as effect sizes may
be reduced during a longer course of a program. All
costs were estimated for two periods, one period when
the stewardship program was implemented (2013) and
one control period (2012).
Three analyses of costs comparisons were per-
formed (Additional file 1: Table S1). Direct costs for
project implementation, for each antibiotic (including
material costs) and for utilization of infectious disease
physician time were specifically allocated to the pro-
ject and directly comparable between the two periods.
A comparison between the intervention period and
control period was made including only these direct
costs. This was designated analysis one. Costs for
nurse time (for preparation and administration of an-
tibiotics) and ward physician time are opportunity
costs not specifically allocated to the project, but dir-
ectly comparable between the two projects. Oppor-
tunity costs in this specific setting means that the
nurses and doctors can potentially be freed and be
available for other tasks. A second comparison, ana-
lysis two, was performed including these costs. The
direct costs for hospital-lengths of stay for patients
treated with antibiotics in each period were included
in analysis three. However, since fewer individuals
were started on antibiotics during the stewardship
intervention and since there were no statistically sig-
nificant differences in patient length-of-stay between
the two periods [9], it can be debated whether the
periods can be considered directly comparable with
regards to total lengths of hospital stay. The same
reasoning applies to mortality and readmission, as
even though the absolute numbers were lower during
the stewardship intervention the proportions were the
same, and no significant differences in 28-day mortal-
ity or 28-day readmissions between the two periods
were demonstrated in the original report [9]. Our
view as that an inclusion of these outcome terms in
the direct cost analysis would not be meaningful, but
rather skew the costs in favour of the intervention.
Thus, data on mortality and on readmissions were
presented (Table 2) but not included in the cost ana-
lyses. An attempt to address the indirect or societal
costs of the program was not performed.
Sensitivity analyses were performed to evaluate the
robustness of the base case results for analysis two by
varying the most important cost drivers; physician
time and nursing time. In addition, the material costs
for preparation of IV antibiotics were varied between
SEK14 and SEK18 instead of SEK15.70 from the base
case analysis. The weekly time for physician audits
was varied from eight hours weekly to six hours per
week. Nurse time for administration of IV antibiotics
was varied between 16 and 20 min per preparation
instead of 18 min as in the base case while the time
for administration of oral antibiotics was varied be-
tween 4 and 8 min instead of 6 min. The sensitivity
analyses were confined to analysis two.
Table 2 Unit or days of utilization per resource category and
study period (costs in SEK, 2015 price level)
Type of resource/cost
unita









Hospital stay (days) 7193 7402



































days (no. of patients)
108 117
Readmission within
28 days (no. of patients)
180 203
aAll antibiotic costs are in full days
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Results
Cost units during the stewardship and the control period
The implementation process of the program itself
demanded 20 h of Infectious Diseases specialist phys-
ician time. The total hospital length of stay for all pa-
tients was 7 193 days for the stewardship period and 7
402 days for the control period. The total days of oral
treatment that were given in-hospital in each cohort was
calculated to be 1 477 in the stewardship cohort and 2
975 in the control cohort. Resource utilization for each
cost unit and cohort is presented in Table 2.
Total cost of each unit of the implementation of an
antimicrobial stewardship program
For each resource category, the total cost per cohort
and the overall balance is presented in Table 3. A nega-
tive balance in a resource category implies that the
stewardship intervention leads to cost-savings in the
actual category. Categories where substantial savings
occurred as a result of the stewardship program in-
clude the cost of nurse time for administration of IV
and oral antibiotics and the material costs of IV antibi-
otics. Moderate cost-savings were found in several cat-
egories of antibiotics (Table 3).
The cost analyses of implementation of the stewardship
program
In analysis one, only direct and comparable costs specific-
ally allocated to the stewardship program were included
(for resource categories included, see Table 3). In this
analysis, the extrapolated yearly cost of the stewardship
program was SEK 161 990 (approximately USD 19 205
and EUR 17 313).
In analysis two, direct and comparable costs as well
as comparable opportunity costs were included. This
allowed the addition of the cost of ward staff time in
Table 3 The total cost of the stewardship intervention per resource category (in SEK, 2015 price level). The total yearly balance in
each analysis is bolded
Type of resource/cost unit Cost during the stewardship
intervention





Implementation costa 13 620 0 13 620 1,2,3
Hospital stay 33 397 099 34 367 486 −970 387 3
ID specialist time 93 920 0 93 920 1,2,3
Resident physician time 61 440 0 61 440 2,3
IV antibiotic treatment, materials 101 610 113 841 −12 230 1,2,3
IV antibiotic treatment, nurse time 616 264 690 440 −74 176 2,3
Oral antibiotic treatment, nurse time 46 850 94 367 −47 517 2,3
cefotaxim 31 826 43 625 −11 799 1,2,3
bensylpenicillin 15 228 14 184 1 044 1,2,3
cloxacillin 9 017 8 059 958 1,2,3
ampicillin 1 512 1 260 252 1,2,3
piperacillin-tazobactam 11 745 8 961 2 784 1,2,3
meropenem 2 510 4 876 −2 366 1,2,3
phenoxymethyl-penicillin 5 759 5 610 149 1,2,3
amoxicillin 3 493 5 159 −1 666 1,2,3
dicloxacillin 5 298 5 886 −588 1,2,3
ciprofloxacin 2 777 5 772 −2 995 1,2,3
trimethoprim-sulfamethoxazole 2 763 3 147 −384 1,2,3
tetracycline 3 415 6 630 −3 215 1,2,3
clindamycin 3 226 6 805 −3 579 1,2,3
metronidazol 1 810 1 569 241 1,2,3
nitrofurantoin 302 527 −225 1,2,3
pivmecillinam 6 523 9 842 −3 319 1,2,3
Analysis one (yearly cost) 800 948 638 958 161 990
Analysis two (yearly cost) 2 684 569 2 679 456 5 113
Analysis three (yearly cost) (89 517 026) (92 034 920) (−2 517 894)
aThe implementation cost was a one-time cost, and was not extrapolated in the yearly calculation
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the evaluation (for included resource categories, see
Table 3). In this analysis, the extrapolated yearly cost of
the stewardship program was SEK 5 113 (approximately
USD 606 and EUR 546).
In analysis three, direct and comparable costs, com-
parable opportunity costs as well as the costs from the
hospital lengths of stay of patients treated with antibi-
otics were included (for included resource categories,
see Table 3). In this analysis, the intervention lead to a
lowering of costs, and the extrapolated yearly saving of
the stewardship was SEK 2 517 894 (approximately USD
298 506 and EUR 269 115).
The results from the sensitivity analyses are presented
in Table 4. Variations on assumptions of the main cost
drivers; physician time, nurse time and material costs for
analysis two resulted in a total range from cost reduction
of SEK 153 574 to a maximum cost of SEK 76 734.
Discussion
Our antimicrobial stewardship was conducted using an
individual audit and direct feedback system involving in-
fectious disease specialists, which would be considered a
costly variant. It was introduced among a geriatric pa-
tient group mainly prescribed low-cost antibiotics in a
setting with no on-going outbreak and low general levels
of antimicrobial resistance. Despite this, the project al-
most fully bears its own costs (an extrapolated yearly
cost of SEK 5 113 or USD 606) when a conservative ap-
proach was performed, including all comparable direct
and opportunity costs objectively attributed to the inter-
vention (analysis two). This analysis neither includes costs
of the beneficial patient outcomes (including length of stay
in hospital), nor the potential long-term societal benefits
of reducing antibiotic misuse/overuse.
The strengths of this study include an individual
characterization and follow-up of each patient receiv-
ing antibiotics during the intervention and control
period, allowing a detailed, correct and comparable
economic analysis. Another strength is that the study
was conducted with no on-going outbreak, reducing
the risks of overestimating the effects and providing
more generalizable results. The limitations include the
limited follow-up time of the intervention and the qua-
siexperimental (before-after) design. Another potential
limitation is that a follow-up only was performed on
patients that actually received antibiotics and not all
patients in the ward. Fewer patients in total were
started on antibiotics during the intervention, and
there was a selection towards more severe infections
during the stewardship intervention. This was indi-
cated by significantly higher levels of C-reactive pro-
tein (CRP) and a significant reduction in antibiotics
only used for less severe infections, such as cystitis,
during the intervention [9]. The direct costs related to
short-term outcomes such as mortality and readmis-
sion were thus not directly comparable between the
two cohorts, but would rather skew the cost analysis in
favour of the intervention, even though they have been
demonstrated using statistical analysis of the propor-
tions to be unchanged following the intervention [9].
In the present work, we have applied three different
cost analyses. Whenever they are possible to calculate, it
is suggested to include all opportunity costs in the ana-
lysis of total antimicrobial stewardship costs [8]. There-
fore, we argue that analysis one does not provide enough
information to be used. Normally, it is suggested that
the total costs related to lengths-of-stay also should be
included in the analysis of each cohort, which is per-
formed in analysis three. However, since only patients
started on antibiotics are included in our analysis, and
since the severities of the infections treated with antibi-
otics in the two periods differ, the two cohorts are diffi-
cult to compare with respect to outcomes including
hospital lengths-of stay. Also, the fact that fewer hospi-
talized patients receive antibiotics will not mean that
there are fewer patients in the ward, and will not mean a
cost reduction for the ward in absolute terms. Due to
these concerns, we believe that analysis three is of least
value and is put in parenthesis. Our belief is that the
most objective analysis is analysis two. We performed a
sensitivity analysis of the costs in analysis two, suggest-
ing that there is uncertainty depending on the assump-
tions made, but that the variation is below 10 % of the
total cost.
Table 4 Results of base case and sensitivity analyses of analysis two, yearly cost (in SEK, 2015 price level)
Type of resource/cost unit Cost during the stewardship intervention Cost during the control period Balance
Base case analysis two 2 684 569 2 679 456 5 113
Physician time 6 h per week 2 583 585 2 679 456 -95 871
Nurse time 16 min for IV antibiotics and 4 min
for oral antibiotics
2 465 934 2 398 211 67 723
Nurse time 20 min for IV antibiotics and 8 min
for oral antibiotics
2 903 205 2 960 908 -57 703
Material cost IV administration SEK14 2 655 963 2 647 407 8 556
Material cost IV administration SEK18 2 723 272 2 722 817 455
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Even though guidelines have been formulated [20], anti-
biotic stewardships can be conducted in several different
ways, and these decisions clearly have implications for the
economic consequences of the program. There have been
a number of examples of stewardship interventions with
distinct cost reductions as a consequence [21]. Most of
these programs have been conducted in areas with high
proportions of antimicrobial resistance and use of high-
cost antibiotics. Most cost-saving interventions that were
not conducted in such areas have other distinctions; in-
cluding mainly younger patients [18], a focus on specific
problem pathogens [22] or on diagnostic interventions
[23]. We believe that the results of our stewardship pro-
gram, targeting mainly elderly hospitalized patients with
underlying diseases in a setting with low rates of anti-
microbial resistance and not in response to an outbreak,
can be generalizable to hospitals in regions with corre-
sponding levels of antimicrobial resistance. This would be
especially true in areas with corresponding population
demographics. We also believe that it is probable that
such a program would work well in a setting with higher
levels of antimicrobial resistance. Also, the use of individ-
ual audits between an ID-specialist and a ward physician
likely provides substantial secondary gains that are not
measurable. There is evidence that ID-specialists can im-
prove patient outcomes and induce cost savings [24], but
some of the most important consequences of our program
have been the bilateral knowledge gain from inter-
disciplinary discussions. Even though a total of 8 h of ID
physician time per week were spent on the stewardship
intervention, this cost analysis demonstrates that the cost
of the program is comparatively low.
Conclusions
The cost analysis provided in this study shows that an
audit-based individual antimicrobial stewardship can
bear its own costs, even in a situation with low general
levels of antimicrobial resistance. The results show that
such programs can be performed at a relatively low cost
also in regions with lower proportions of antimicrobial
resistance. However, to combat antimicrobial resistance
on a larger scale, a multitude of simultaneous measures
are needed, tailored to each specific setting [25].
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